Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £19.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Gordon CFA is a 3-star analyst with an average return of 5.3% and a 48.28% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as Novo Nordisk, GlaxoSmithKline, and Galderma Group AG.
In addition to Barclays, GlaxoSmithKline also received a Sell from J.P. Morgan’s Zain Ebrahim in a report issued yesterday. However, on March 26, Berenberg Bank reiterated a Hold rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 323 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK announces China NMPA accepted for review NDA for bepirovirsen
- GSK announces China’s NMPA approved Exdensur as add-on traetment
- GSK’s Hepatitis B Drug Bepirovirsen Enters China Regulatory Review as Potential First-in-Class Cure
- GSK Expands Treasury Stock as Share Buyback Programme Advances
- GSK Wins China Approval for First Ultra-Long-Acting Biologic Exdensur in Severe Asthma
